A number of HESI committees will have presentations and posters at the Society of Toxicology Meeting in Nashville, TN.
Society of Toxicology Meeting 2023
March 19, 2023 – March 23, 2023
Nashville, TN, USA
To establish a platform where an international network of experts from multiple sectors (public and private sector research scientists, regulators, clinicians, health foundations, and technology developers) can collaborate sharing knowledge, experience, and resources in the rapidly evolving field of cell therapy.
HESI CT-TRACS is proud to be a partner in NC3Rs 2022 CRACK-IT challenge “T-ALERT: Animal-free tumourigenicity assessment of CAR-T and other genetically modified T cells”. CRACK-IT challenges provides UK and EU-based academics and SMEs with the opportunity to apply to develop new 3Rs tools, technologies or approaches and engage with new partners. The T-ALERT Challenge aims to develop an in vitro assay that can reliably evaluate tumourigenicity of human-engineered T cell therapies with the potential to be applied to multiple immune cell types.
As a partner, HESI and the CT-TRACS committee will help to create productive relationship between the challenge awardees and organisations that have expertise, data, or other resources that could support successful Challenge dissemination of the resulting technology. The HESI CT-TRACS Tumorigenicity Working Group will leverage its successful track record of multi-laboratory evaluation of relevant methods and assays in support of tumorigenicity evaluation of cell therapy products in support of the challenge winners.
This working group aims to identify current approaches, gaps, and needs in monitoring/evaluating the fate and activity of cells after their administration in vivo, to assess the safety of cell-based therapies.
This working group aims to address concerns regarding the potential for tumorigenicity of PSC-derived products by assessing and/or developing methodologies and approaches that could support tumorigenicity evaluation.
Medicines Evaluation Board, The Netherlands
AstraZeneca
March 19, 2023 – March 23, 2023
Nashville, TN, USA
A number of HESI committees will have presentations and posters at the Society of Toxicology Meeting in Nashville, TN.
November 14, 2022
Denver, Colorado, USA
Don’t miss the overview of CT-TRACS’ Advanced Sequencing project as well at a talk by the GTTC on the HESI Nitrosamine Subgroup at the upcoming American College of Toxicology Annual Meeting.
May 25, 2022
London, United Kingdom
HESI's Cell Therapy – TRAcking, Circulation & Safety (CT-TRACS) Committee will present preliminary results of their pilot project “New approaches for identification of potential off-target mutations associated with CRISPR genome editing in cell therapies” at the Advanced Therapies 2022 Congress, London, UK, as ...
September 28, 2021
Zoom webinar, co-organized by EATRIS and the HESI CT-TRACS Committee
The HESI Cell Therapy - TRAcking, Circulation, & Safety (CT-TRACS) Committee will present a webinar on September 28, 2021 featuring three speakers who will share regulatory perspectives from both sides of the Atlantic. This activity is party of the CT-TRACS Committee's efforts to continue filling the knowledge gap about ...
June 22, 2021 – June 24, 2021
Virtual conference, hosted by Informa Connect
The HESI Cell Therapy - TRAcking, Circulation, & Safety (CT-TRACS) Committee will be represented at the Next Generation CAR & T-Cell Therapies Conference on June 22, 2021 from 10:30am-10:50am PST in a presentation titled "Creating a Feedback Loop Between Clinical Trials and Translational Science for Product ...
September 3, 2020
Webinar, hosted by the National Heart, Lung, and Blood Institute (NHLBI) PACT Program
The HESI Cell Therapy - TRAcking, Circulation, & Safety (CT-TRACS) Committee is pleased to present a webinar on "Methods for Cellular Tracking Cells In Vivo and Following Biodistribtion" in collaboration with the National Heart, Lung, and Blood Institute (NHLBI) PACT Program. Cell therapies show great ...
Workshop Program Outline (subject to change)
Wednesday, 21 October 2020
Thursday, 22 October 2020
For more information, please contact the PATB Committee's Senior Scientific Program Manager, Dr. Lucilia Mouriès at lmouries@hesiglobal.org.
[post_title] => Cell Therapy - TRAcking, Circulation, & Safety (CT-TRACS) Committee Regulatory Perspectives Webinar [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cttracs-committee-regulatory-perspectives-webinar [to_ping] => [pinged] => [post_modified] => 2022-02-17 16:41:10 [post_modified_gmt] => 2022-02-17 16:41:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://hesiglobal.org/event/patb-committee-protein-toxins-workshop-copy/ [menu_order] => 0 [post_type] => event [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 24037 [post_author] => 2 [post_date] => 2021-06-01 16:52:13 [post_date_gmt] => 2021-06-01 16:52:13 [post_content] => [post_title] => Next Generation CAR & T-Cell Therapies Conference [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => next-generation-car-t-cell-therapies-conference [to_ping] => [pinged] => [post_modified] => 2021-10-08 14:18:40 [post_modified_gmt] => 2021-10-08 14:18:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://hesiglobal.org/?post_type=event&p=24037 [menu_order] => 0 [post_type] => event [post_mime_type] => [comment_count] => 0 [filter] => raw ) [5] => WP_Post Object ( [ID] => 22879 [post_author] => 13 [post_date] => 2020-08-03 13:40:52 [post_date_gmt] => 2020-08-03 18:40:52 [post_content] => Methods for Cellular Therapies: Tracking Cells In Vivo and Assessing Biodistribution in PatientsThe HESI Cell Therapy - TRAcking, Circulation, & Safety (CT-TRACS) Committee is pleased to present a webinar on "Methods for Cellular Therapies: Tracking Cells In Vivo and Assessing Biodistribution in Patients" in collaboration with the National Heart, Lung, and Blood Institute (NHLBI) PACT Program.
Details:
Speakers:
Cell therapies show great therapeutic promise in the fields of regenerative medicine and immunotherapy. To realize their full clinical potential, there is a need for greater understanding of their mode of action, how they migrate after administration to deliver their therapeutic benefits, their persistence at sites of action, and whether their properties, localization, or distribution may cause safety issues. Currently, there are several existing and many emerging tools available to develop pharmacokinetic data on these cell-derived therapies to improve our understanding of the mechanism of action and demonstrate on-target delivery, but adoption by clinical investigators has been limited.
In this web seminar, the CT-TRACS Committee speakers will provide an overview of technologies currently available for use in patients, how these are relevant to evaluate safety and efficacy aspects of cellular therapies, and the importance of collaboration to address challenges and needs facing the translation of cell therapies into the clinic.
The CT-TRACS Committee provides a neutral platform for cell therapy developers, researchers, regulators, imaging specialists, and other stakeholders to interact, discuss current challenges, and identify best practices to improve confidence in the safety and efficacy of these therapies.
Webinar Objectives:
Additional details can be found via the webinar e-flyer here. For more information, please contact the CT-TRACS Committee's Senior Scientific Program Manager, Dr. Lucilia Mouriès at lmouries@hesiglobal.org.
[post_title] => CT-TRACS Committee and NIH/NHLBI PACT Program Joint Webinar [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cttracs-committee-pact-program-webinar [to_ping] => [pinged] => [post_modified] => 2020-10-29 13:38:55 [post_modified_gmt] => 2020-10-29 13:38:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://hesiglobal.org/?post_type=event&p=22879 [menu_order] => 0 [post_type] => event [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 6 [current_post] => -1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 26333 [post_author] => 16 [post_date] => 2023-01-10 20:48:12 [post_date_gmt] => 2023-01-10 20:48:12 [post_content] => [post_title] => Society of Toxicology Meeting 2023 [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => society-of-toxicology-meeting-2023 [to_ping] => [pinged] => [post_modified] => 2023-01-10 20:56:01 [post_modified_gmt] => 2023-01-10 20:56:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://hesiglobal.org/?post_type=event&p=26333 [menu_order] => 0 [post_type] => event [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 10 [max_num_pages] => 2 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => 1 [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => 1 [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 020be1221771896102561d7de2b3487b [query_vars_changed:WP_Query:private] => 1 [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )Cytotherapy, 2019
Pluripotent stem cells offer the potential for an unlimited source for cell therapy products. However, there is concern regarding the tumorigenicity of these products in humans, mainly due to the possible unintended contamination of undifferentiated cells or transformed cells. Here, we critically review currently available ...
Cytotherapy, 2021
Cell-based therapies have been making great advances toward clinical reality. Despite the increase in trial activity, few therapies have successfully navigated late-phase clinical trials and received market authorization. One possible explanation for this is that additional tools and technologies to enable their ...
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.